Fundraising Fox
OmniAb
NASDAQ: OABIEmeryville, US · Founded 2022 · Delaware corporation · 1 known investors
Find your way into OmniAb
Sign up to see every warm intro you have to OmniAb
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OmniAb team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.
Founders & leadership
AN
Amechi NwachukuChief Operating OfficerChief Operating Officer at OmniAb. Nwachuku has held leadership roles across biotech, medtech, pharmaceuticals, and consumer health, with experience in P&L management and strategy development across international teams.
KA
Kurt A. GustafsonExecutive Vice President, Finance and Chief Financial OfficerKurt Gustafson holds a BA in Accounting from North Park University and an MBA from UCLA. He spent over a decade in finance roles at Amgen, including Treasurer and VP of Corporate Financial Planning and Analysis, before serving as CFO of Amgen's International Operations and later as CFO at Halozyme Therapeutics and Spectrum Pharmaceuticals, where he led financing rounds and strategic acquisitions. He joined OmniAb as CFO in March 2022.
Board
JH
John HigginsBoard director
CR
Carolyn R. BertozziBoard director
JC
Jennifer CochranBoard director
PJ
Philip J. GotwalsBoard director
SL
Steve LoveBoard director
SC
Steve CrouseBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$30M disclosed across 1 round · 2025
▶$30MraisedSep 2025 · 15 investors · BiotechnologyRule 506(b)
▶$30MraisedSep 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carolyn R. BertozziDirector
- Kurt GustafsonExecutive Officer
- John HigginsDirector
- Jennifer CochranDirector
- Matthew W. FoehrExecutive Officer, Director
- Charles BerkmanExecutive Officer
- Philip J. GotwalsDirector
- Steve LoveDirector
- Steve CrouseDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
AbcamSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies working in the same space as OmniAb.
In the news
Frequently asked questions
- What does OmniAb do?
- OmniAb develops transgenic animal platforms engineered to generate human antibodies for therapeutic drug discovery, serving biopharmaceutical researchers and drug developers.
- Who are OmniAb's investors?
- OmniAb's investors include Avista.
- How much funding has OmniAb raised?
- OmniAb has disclosed $30M raised across 1 round.
- Where is OmniAb headquartered?
- OmniAb is headquartered in Emeryville, US.